Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Parenteral Anesthetics: Overview

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

From wastewater treatment to energy devices: A comprehensive review on biochar utilization and reuse pathways.

The Science of the total environment·2026

Same author

HPV-Negative Basaloid Squamous Cell Carcinoma of the Rectum: An Exceptionally Rare Entity.

ACG case reports journal·2026

Same author

Near-Infrared Spectroscopy for Off-Pump Pediatric Cardiac Surgery.

World journal for pediatric & congenital heart surgery·2026

Same author

Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes.

Hepatology international·2025

Same author

Continuous right-to-left ductal flow in a newborn.

Annals of pediatric cardiology·2025

Same author

Pediatric cardiac surgical tourism in LMIC's-the paradox.

Indian journal of thoracic and cardiovascular surgery·2025

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

Voriconazole in newborns.

Vikas Kohli¹, Vikas Taneja, Poonam Sachdev

¹Apollo Center for Advanced Pediatrics, Pediatric Cardiology and Cardiac Surgery Unit, Indraprastha Apollo Hospital, New Delhi, India. vkohli_md@yahoo.com

Indian Pediatrics

|March 28, 2008

Summary

This summary is machine-generated.

This study shows voriconazole is safe for critically ill newborns with heart conditions. It can be used with other cardiac medications without adverse effects.

More Related Videos

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

A Neonatal Rodent Model of Retroorbital Vein Injection

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jul 6, 2026

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

A Neonatal Rodent Model of Retroorbital Vein Injection

A Neonatal Rodent Model of Retroorbital Vein Injection

Published on: February 23, 2024

Area of Science:

Neonatal Medicine
Pharmacology
Cardiology

Background:

Voriconazole is a newer systemic antifungal agent.
Limited data exists on its use in newborns.
Fungal infections pose risks to critically ill infants.

Observation:

This case series reports on the use of voriconazole in critically ill newborns with cardiac disease.
The infants received voriconazole along with other cardiac medications.
Close monitoring for drug interactions and side effects was performed.

Findings:

Voriconazole was safely administered to critically ill newborns with cardiac conditions.
No significant drug interactions were observed between voriconazole and concurrent cardiac therapies.
No adverse side effects were reported during the treatment period.

Implications:

Voriconazole may be a safe and effective antifungal option for neonates with cardiac disease.
This finding expands treatment options for fungal infections in vulnerable infant populations.
Further research can explore optimal dosing and long-term outcomes.